Beyond resourcing: Delivering strategic value in clinical development
Why hybrid operating models are shaping the future of pharma biometrics and data science
The future will not be defined by whether sponsors choose FSP, FSO or hybrid as a label. It will be defined by selecting the right model for the right organisational context, and by combining sponsor expertise, CRO capability, technology, governance and clinical data science into a connected decision ecosystem where that creates value.
Driving transformation through hybrid biometrics models
For many years, clinical development outsourcing has often been framed through a relatively simple lens: should a sponsor use a Functional Service Provider model or a Full-Service Outsourcing model? Both models continue to have clear stand-alone value. FSP can provide embedded expertise, continuity and sponsor-directed control. FSO can offer broader accountability, delivery ownership and reduced operational burden. Hybrid models should not be positioned as a replacement for either model, but as a potential “best of both worlds” solution when the sponsor’s size, portfolio complexity, governance maturity and transformation objectives support that approach.
The stronger question is no longer which model we should use. The stronger question is what outcomes the operating model must deliver, and what combination of people, process, technology, governance and partner accountability is required to deliver them.
This shift matters because the nature of clinical development has fundamentally changed. Sponsors are expected to make faster decisions across increasingly complex portfolios while navigating fragmented data landscapes, decentralised trial models, growing regulatory expectations and ongoing pressure to improve development efficiency.
As data volumes expand and study designs become more sophisticated, many organisations are discovering that traditional operating models were not built to provide the visibility, agility and decision support now required. The challenge is no longer simply accessing capacity. It is creating an environment where clinical data can be transformed into timely, confident decisions at both study and portfolio level.
This evolution is changing the role of biometrics and data science. Functions once viewed primarily as delivery engines are increasingly becoming strategic contributors to programme and portfolio decision-making.
In this environment, hybrid operating models are becoming one of the most important transformation levers available to sponsors. When designed well, they do not simply blend FSP and FSO. They create a connected delivery ecosystem that combines embedded sponsor knowledge, scalable CRO capability, clinical data science, technology-enabled oversight, automation and clear governance.
Importantly, hybrid is not the right answer for every organisation or every portfolio. For some sponsors, a focused FSP model may continue to provide the strongest balance of control, continuity and embedded knowledge. For others, FSO may remain the most effective route to accountability, simplicity and operational transfer. The value of hybrid lies in applying it selectively, where the model can solve specific delivery challenges without adding unnecessary complexity.
Why traditional models are being challenged
Traditional outsourcing models were often designed around capacity. They helped sponsors access additional resources, manage peaks in demand and deliver functional activities across clinical data management, biostatistics, programming and related disciplines. Those needs remain important, but capacity alone is no longer sufficient.
Modern biometrics delivery must address a broader set of expectations: faster insight generation, earlier risk detection, improved portfolio visibility, resilient delivery, quality by design, stronger submission readiness and more consistent decision support. This requires a model that is not only resourced but orchestrated.
The benefits of hybrid operating models
Is hybrid the right fit for your organisation?
A hybrid model works best when it is designed around a clear organisational need rather than adopted as a default sourcing strategy. Sponsors should assess whether hybrid delivery will genuinely improve oversight, scalability, quality, speed or portfolio insight, and whether the organisation has the maturity to manage a more integrated operating construct.
If these conditions are not sufficiently mature, sponsors may be better served by strengthening their existing FSP or FSO model first, then moving toward hybrid in targeted stages. This protects the value of proven delivery constructs while creating a realistic pathway toward broader transformation.
How sponsors can move toward a hybrid future
Transformation does not need to be disruptive. A pragmatic pathway is to protect what is working, strengthen governance, define which portfolio segments require which model, and then evolve capability in stages. This creates a route to higher-value delivery while reducing the risk of operational disruption.
A staged roadmap usually starts with stabilising the current delivery base, then integrating model components, industrialising repeatable ways of working, and finally embedding analytics, automation and AI-ready workflows. This allows transformation to move at the pace of the portfolio rather than forcing the portfolio to absorb unnecessary change.
Industry insights and implications
Industry discussions increasingly indicate that sponsors are evaluating outsourcing decisions within the broader context of operating model design, governance and technology strategy. As clinical development becomes more data-intensive and digitally enabled, there is growing focus on how expertise, processes and decision-making are organised across sponsors and partners.
Conclusion
The future of pharma biometrics and data science will not be defined by FSP or FSO labels alone. It will be defined by how effectively organisations create connected, intelligent and governed operating models that translate clinical data into better decisions.
Hybrid models represent one potential route to achieving this. They can help sponsors to retain strategic control where it matters, increase accountability where it adds value, scale through global capability, and integrate technology and data science more effectively across the development lifecycle.
For sponsors facing increasing complexity, the opportunity is clear: move beyond sourcing constructs and design operating models around portfolio outcomes. The question facing sponsors is no longer which outsourcing model is best. It is whether their operating model is equipped to meet the demands of the next generation of clinical development.